<DOC>
	<DOCNO>NCT00568971</DOCNO>
	<brief_summary>The purpose study evaluate efficacy weekly docetaxol combine cisplatin 5-Fu patient AGC .</brief_summary>
	<brief_title>Study Weekly DCF Treat Advanced Gastric Cancer</brief_title>
	<detailed_description>Recently , multi-center , open-label randomized phase III study ( V325 ) , compare control arm CF regimen , DCF show high efficacy term response rate , time progression overall survival . But regimen increase grade 3-4 neutropenia ( 82 % vs 57 % ) febrile neutropenia infection ( 29 % vs 12 % ) . We begin study weekly DCF patient advance gastric cancer evaluate efficacy less 3-week ' regimen .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Age 18 70 year Patients histologically confirm , unresectable , recurrent and/or metastatic gastric adenocarcinoma ECOG performance status ≤1 , life expectancy 3 month , Normal laboratory finding : absolute neutrophil count platelet count ≥ 2.0×109/L 80×109/L , respectively , hepatic function ( total serum bilirubin ≤ UNL , transaminases ≤ 1.5 time upper normal limit ) renal function ( calculated creatinine clearance ≥ 60 ml/min ) . Measurable disease accord RECIST . Pregnant lactate woman Serious uncontrolled disease intercurrent infection The evidence CNS metastasis History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Received chemotherapy regimen metastasis Used taxane adjuvant setting Participated clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>DCF</keyword>
	<keyword>Advanced gastric cancer</keyword>
	<keyword>Phase II study</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Toxicity</keyword>
</DOC>